1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

BioMarin to pay $840m for GSK castoff

 
• By Sukaina Virji

BioMarin Pharmaceutical is to buy rare disease-focused Prosensa for $680m in cash and $160m in contingent milestones if Prosensa's Duchenne muscular dystrophy product – the GSK-reject drisapersen – is approved quickly in the US and Europe.

BioMarin Pharmaceutical is to buy rare disease-focused Prosensa for $680m in cash and $160m in contingent milestones if Prosensa's Duchenne muscular dystrophy product – the GSK-reject drisapersen – is approved quickly in the US and Europe.

Drisapersen had been partnered with GlaxoSmithKline but the big pharma pulled out of the deal following drisapersen's failure in the Phase III DEMAND study last year, which showed that the antisense oligonucleotide did not meet the primary endpoint of statistically significant improvement in the six-minute walking distance (6MWD) test compared with placebo (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.